ALS, or amyotrophic lateral sclerosis, can sometimes be difficult to diagnose or to predict how quickly the disease is likely ...
Diagnosing ALS is a challenge, but new research has found a highly effective way to detect and track the disease using blood ...
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager ...
Innovative platform trial revolutionizes ALS research by testing multiple treatments simultaneously, offering new hope ...
PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company pioneering a breakthrough non-invasive treatment approach for amyotrophic lateral sclerosis (ALS), is pleased to ...
Celeb Tattler on MSN1d
'The First Time Ever I Saw Your Face' Singer, Dies at 88Flack reached her breakthrough moment with "First Take" which she released in 1969 and included "The First Time Ever I Saw ...
Shawn Sarbacker was in the nets in 1986, the first time the Spuds advanced to the section championship game before losing to ...
Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkersAPST Research data includes thousands of people living with ALS ...
At the booming biotech campus of Pegasus Park in Dallas, up-and-coming biopharmaceutical company GenrAb believes it’s onto ...
While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...
NEW research has shown that pridopidine, a sigma-1 receptor agonist, does not exhibit a significant impact on the progression of amyotrophic lateral sclerosis (ALS) over a 24-week period.
Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback